Oral antiplatelet therapy in PCI patients.

The use of percutaneous coronary intervention (PCI) in the treatment of obstructive coronary artery disease has expanded rapidly in the past decade. Despite the extensive technological advancements in the field, pharmacotherapy has remained a cornerstone in the overall treatment strategy. Oral antiplatelet therapy has become an essential component of therapy with acute coronary syndromes and in PCI by improving clinical outcomes. This article reviews the antiplatelet options for patients undergoing PCI, including aspirin, ADP receptor blockers, and glycoprotein IIb/IIIa inhibitors.